Table 1.
Likely to use future HIV prevention product among HIV‐negative men in three US cities, 2018 (n = 782)
| Characteristic | n (% overall) | Future HIV prevention product | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long‐acting injectable | Event‐based pills | Penile gel | Anal gel | Anal suppository | |||||||
| n (%) | AOR (95% CI) | n (%) | AOR (95% CI) | n (%)n (%) | AOR (95% CI) AOR (95% CI) | n (%) | AOR (95% CI) | n (%) | AOR (95% CI) | ||
| Overall | 782 (100) | 560/755 (74) | – | 501/749 (67) | – | 478/752 (64) | – | 407/751 (54) | – | 319/752 (42) | – |
| Current daily PrEP use | |||||||||||
| Yes | 243 (32) | 213 (88)* | 3.29 (2.12 to 5.11)* | 125 (52)* | 0.37 (0.27 to 0.52)* | 117 (48)* | 0.42 (0.30 to 0.59)* | 114 (47)* | 0.71 (0.51 to 0.97)* | 87 (36)* | 0.74 (0.53 to 1.03)† |
| No (ref) | 512 (68) | 347 (68) | 376 (74) | 361 (71) | 293 (58) | 232 (45) | |||||
| Unprotected (condomless/PrEPless) anal sex (3mon) | |||||||||||
| Yes | 284 (36) | 206 (73) | 1.16 (0.81 to 1.66) | 203 (73)* | 1.30 (0.92 to 1.84) | 211 (74)* | 1.79 (1.27 to 2.52)* | 167 (59)* | 1.22 (0.89 to 1.67) | 141 (50)* | 1.48 (1.08 to 2.02)* |
| No (ref) | 497 (64) | 365 (73) | 314 (63) | 287 (58) | 253 (51) | 186 (38) | |||||
| Race/ethnicity | |||||||||||
| Black | 155 (20) | 101 (65)* | 0.54 (0.34 to 0.84)* | 97 (64) | 0.87 (0.57 to 1.33) | 108 (69)* | 1.54 (1.00 to 2.38)† | 83 (54) | 0.91 (0.61 to 1.36) | 71 (46) | 1.26 (0.84 to 1.89) |
| Hispanic/Latino | 123 (16) | 90 (73) | 0.84 (0.49 to 1.41) | 88 (73) | 2.12 (1.28 to 3.50)* | 87 (71) | 2.29 (1.40 to 3.73)* | 68 (56) | 1.31 (0.84 to 2.03) | 52 (42) | 1.34 (0.86 to 2.07) |
| Other/mixed | 98 (12) | 61 (62) | 0.46 (0.27 to 0.76)* | 73 (74) | 1.90 (1.11 to 3.25)* | 65 (66) | 1.61 (0.98 to 2.65)† | 56 (58) | 1.39 (0.87 to 2.23) | 43 (44) | 1.36 (0.85 to 2.17) |
| White (ref) | 405 (52) | 319 (79) | 259 (64) | 238 (59) | 213 (53) | 161 (40) | |||||
| Age group, years | |||||||||||
| 18 to 29 | 353 (45) | 247 (70)* | 1.06 (0.70 to 1.63) | 230 (65) | 0.93 (0.62 to 1.40) | 215 (61)* | 0.53 (0.35 to 0.80)* | 180 (51)* | 0.57 (0.39 to 0.84)* | 130 (37)* | 0.56 (0.38 to 0.81)* |
| 30 to 39 | 239 (31) | 195 (82) | 1.89 (1.17 to 3.07)* | 164 (69) | 1.17 (0.75 to 1.82) | 147 (62) | 0.58 (0.37 to 0.91)* | 123 (52) | 0.62 (0.41 to 0.93)* | 103 (43) | 0.73 (0.49 to 1.09) |
| 40+ (ref) | 189 (24) | 129 (68) | 123 (66) | 136 (72) | 117 (63) | 94 (50) | |||||
| Education level | |||||||||||
| ≤ Post HS (ref) | 280 (36) | 192 (69) | 188 (68) | 181 (65) | 160 (58) | 119 (43) | |||||
| 4‐year college | 282 (36) | 215 (76) | 1.16 (0.77 to 1.76) | 187 (66) | 1.13 (0.76 to 1.69) | 182 (65) | 1.50 (1.02 to 2.23)* | 148 (53) | 0.85 (0.59 to 1.22) | 117 (41) | 1.07 (0.75 to 1.55) |
| ≥ Post college | 217 (28) | 162 (75) | 1.00 (0.63 to 1.58) | 140 (65) | 1.07 (0.70 to 1.64) | 133 (62) | 1.28 (0.84 to 1.96) | 110 (51) | 0.79 (0.53 to 1.16) | 89 (41) | 1.03 (0.69 to 1.53) |
| City/MSA | |||||||||||
| Atlanta (ref) | 276 (35) | 201 (73) | 192 (70)* | 178 (64) | 159 (58) | 113 (41) | |||||
| Detroit | 237 (31) | 174 (73) | 1.08 (0.70 to 1.67) | 164 (69) | 0.84 (0.56 to 1.26) | 160 (68) | 1.16 (0.78 to 1.73) | 123 (52) | 0.79 (0.55 to 1.15) | 103 (43) | 1.14 (0.79 to 1.66) |
| New York | 268 (34) | 196 (73) | 0.96 (0.63 to 1.45) | 161 (61) | 0.57 (0.38 to 0.83)* | 160 (60) | 0.78 (0.54 to 1.15) | 138 (52) | 0.80 (0.56 to 1.15) | 111 (42) | 1.02 (0.71 to 1.46) |
Multivariable regression models include all variables listed within column. AOR, adjusted odds ration; CI, confidence interval; HS, high school; MSA, metropolitan statistical area; –, not applicable.
*
p < 0.05
†
p < 0.10.